Founded in 2020 by Temple University chemist Christian Schafmeister, Ladder Bio is a Blue Bell biotechnology company developing Spiroligomer™ molecules—synthetic, ladder-shaped compounds designed for targeted drug discovery. Its platform combines rational molecular design with libraries containing billions of compounds, pursuing therapeutics and diagnostic applications where conventional small molecules and biologics can fall short. Formerly known as ThirdLaw Molecular, the company has also received more than $16.9 million in non-dilutive funding from the U.S. Department of Defense and the Defense Threat Reduction Agency for biosecurity-related work.
Financial Conflicts of Interest Policy (TLM-FIN-01)
Compliance program
ResilienceNational Resilience, Inc. is a technology-focused biomanufacturing company founded in 2020 to broaden access to complex medicines and strengthen biopharmaceutical supply chains. It operates an end-to-end manufacturing network across North America, supporting development and production of medicines from early phase through commercial manufacturing. Its facilities produce drug substances and drug products, including cell therapies and vaccines.BLUE ASH, OH
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Rapafusyn PharmaceuticalsEmerging from Johns Hopkins professor Jun O. Liu’s laboratory, Rapafusyn Pharmaceuticals develops non-degrading molecular-glue medicines designed to reach hard-to-drug intracellular and transmembrane targets. Based on its RapaGlue™ platform, the Baltimore biotech is advancing an early pipeline that includes an ENT1 inhibitor for acute kidney injury, an area where the company says no approved preventive therapies exist. Its discovery engine combines AI-enabled machine learning with a DNA-encoded library containing more than 8 billion non-degrading glues.BALTIMORE, MD
Trailhead BiosystemsFounded in 2015 as a Cleveland Clinic and Case Western Reserve University spinout, Trailhead Biosystems is a Beachwood biotechnology company built around the research of founder Jan Jensen. It is known for HD-DoE®, a data-driven platform that uses computational modeling and robotic experimentation to direct induced pluripotent stem cells into specialized human cells for researchers developing new medicines and cell therapies.BEACHWOOD, OH